Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > PHAR Pharming Group > Key Indicators
PHAR Pharming Group
13.450
+0.080+0.60%
Post Mkt Price
13.4500.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
8.34% -228.1932 35.79% -202.4938 34.04% -227.101 64.55% 274.8119
Receivable Turnover(T)
-0.26% 6.6121 -12.48% 5.7462 -3.35% 6.278 -0.53% 9.5546
Inventory Turnover(T)
-44.54% 0.5778 -36.37% 0.706 -35.39% 0.825 -35.66% 0.8718
Fixed Assets Turnover(T)
-16.04% 6.2054 -27.54% 5.9877 -34.69% 7.5096 -39.73% 7.2513
Total Asset Rate(T)
-4.64% 0.5203 -12.55% 0.5023 -13.34% 0.504 -28.04% 0.4872
ROIC
404.63% 10.245% -24.36% 7.039% -48.08% 5.504% -66.96% 5.761%
ROE
13.27% 15.423% -47.94% 10.480% -77.22% 5.754% -68.54% 8.494%
ROA
24.99% 7.754% -42.18% 5.174% -74.38% 2.729% -67.46% 3.919%
FCF to Sales
-18.76% 12.448% -64.63% 7.649% -70.96% 8.549% -67.44% 10.623%
FCF to Net Income
-38.02% 83.532% -46.50% 74.265% -1.82% 157.875% -27.98% 132.071%
Efficiency Ratios
ROE 5 Year Average
-- -- -- -- -- -- 24.51% -46.585%
ROA 5 Year Average
-- -- -- -- -- -- 64.19% -2.532%
Average 5 Years ROIC
-- -- -- -- -- -- 204.39% 2.683%
Profitability Ratios TTM
Gross Margin
2.92% 91.691% 0.60% 89.841% 0.73% 89.513% 0.52% 89.369%
Operating Margin
-9.64% 15.745% -60.84% 11.118% -75.04% 7.701% -73.41% 9.558%
Net Margin
31.07% 14.903% -33.88% 10.300% -70.43% 5.415% -54.79% 8.043%
EBITDA Margin
125.41% 0.2913% 16.41% 0.2563% -21.69% 0.1987% -10.81% 0.2453%
R & D Expense Ratio
1.79% 30.090% 73.72% 37.280% 85.66% 36.910% 94.93% 35.380%
Sales Expense Ratio
24.63% 35.520% 24.01% 33.210% 15.68% 30.610% 22.90% 29.890%
Administration Expense Rate
45.27% 13.830% 33.83% 11.670% 56.08% 11.300% 77.34% 11.190%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-18.46% 67.530% -13.30% 72.561% -1.01% 79.097% -5.21% 81.623%
Total Assets to Common Equity
-7.84% 190.919% -5.12% 197.275% -7.82% 202.451% -9.72% 205.952%
Debt to Asset Ratio
-18.37% 69.503% -13.25% 74.624% -1.51% 81.325% -5.03% 83.851%
Current Ratio
4.12% 5.3979 -0.54% 5.2238 56.46% 5.558 55.71% 5.3333
Quick Ratio
0.71% 4.6587 -4.10% 4.5299 50.94% 4.8973 52.15% 4.6934
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -- -- -69.31% 8.762%
Revenue CAGR(5Y)
-- -- -- -- -- -- -20.58% 64.136%
Net Income CAGR(3Y)
-- -- -- -- -- -- -- -17.599%
FCF 1 Year Growth
-- -- -- -- -- -- -238.55% -71.646%
FCF CAGR(3Y)
-- -- -- -- -- -- -183.17% -20.392%
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.
CEO: Dr. Sijmen (Simon) de Vries, M.D.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist